We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00500292
Recruitment Status : Completed
First Posted : July 12, 2007
Results First Posted : May 24, 2011
Last Update Posted : January 25, 2018
Sponsor:
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )

Brief Summary:
The purpose of this study is to determine whether treatment with ZACTIMA (vandetanib) in combination with FOLFOX is more effective than FOLFOX alone for colorectal cancer in patients who have failed therapy with an irinotecan and fluoropyrimidine containing regimen.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Drug: Vandetanib Drug: FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 109 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer in Patients Who Have Failed Therapy With an Irinotecan and Fluoropyrimidine Regimen
Study Start Date : March 2007
Primary Completion Date : March 2008
Study Completion Date : November 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Vandetanib
U.S. FDA Resources

Arm Intervention/treatment
Placebo Comparator: 1
FOLFOX + Placebo vandetanib
Drug: FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid
intravenous infusion
Experimental: 2
FOLFOX + low dose vandetanib
Drug: Vandetanib
once daily oral tablet two dose strengths
Other Names:
  • AZ6474
  • ZACTIMA™
  • SAR390530
Drug: FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid
intravenous infusion
Experimental: 3
FOLFOX + high dose vandetanib
Drug: Vandetanib
once daily oral tablet two dose strengths
Other Names:
  • AZ6474
  • ZACTIMA™
  • SAR390530
Drug: FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid
intravenous infusion



Primary Outcome Measures :
  1. Number of Patients With an Objective Disease Progression Event [ Time Frame: RECIST tumour assessments carried out at screening and then as per site clinical practice until objective progression. The only additional mandatory tumour assessment visit is at the point of data cut-off (5 March 2008 +/-3 days) ]
    Number of patients with objective disease progression or death (by any cause in the absence of objective progression)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Progression on or following treatment for metastatic colorectal cancer
  • Have failed therapy with an irinotecan and fluoropyrimidine containing regimen
  • Have World Health Organisation (WHO) performance status 0-2 and life expectancy >12 weeks

Exclusion Criteria:

  • Previous treatment with small molecule tyrosine kinase inhibitors of VEGFR or EGFR Prior monoclonal antibodies are permitted, (eg, cetuximab, bevacizumab)
  • Previous adjuvant therapy with irinotecan within 12 months of randomisation
  • More than one prior course of chemotherapy for treatment of metastatic colorectal cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00500292


Locations
France
Research Site
Lille Cedex, France
Research Site
Toulouse Cedex 9, France
Hungary
Research Site
Budapest, Hungary
Research Site
Debrecen, Hungary
Research Site
Szeged, Hungary
Korea, Republic of
Research Site
Seoul, Korea, Republic of
Slovakia
Research Site
Bratislava, Slovakia
Research Site
Poprad, Slovakia
Research Site
Trnava, Slovakia
Research Site
Zilina, Slovakia
Spain
Research Site
Hospitalet deLlobregat, Spain
Research Site
Oviedo, Spain
Research Site
Santander, Spain
Taiwan
Research Site
Taipei, Taiwan
Research Site
Tao-Yuan, Taiwan
Sponsors and Collaborators
Genzyme, a Sanofi Company
Investigators
Study Director: Clinical Sciences & Operations Sanofi

Additional Information:
Responsible Party: Genzyme, a Sanofi Company
ClinicalTrials.gov Identifier: NCT00500292     History of Changes
Other Study ID Numbers: D4200C00047
2006-005022-23 ( EudraCT Number )
LPS15025 ( Other Identifier: Sanofi )
First Posted: July 12, 2007    Key Record Dates
Results First Posted: May 24, 2011
Last Update Posted: January 25, 2018
Last Verified: January 2018

Keywords provided by Sanofi ( Genzyme, a Sanofi Company ):
colorectal
cancer
zactima

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Oxaliplatin
Fluorouracil
Leucovorin
Levoleucovorin
Folic Acid
Antineoplastic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antidotes
Protective Agents
Vitamin B Complex
Vitamins
Micronutrients
Growth Substances
Hematinics